SynopsisELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The global Acquired hemophilia A Treatment market size is expected to reach US$ 996.1 million by 2029, growing a.....
SynopsisAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Aldesleukin market size is expected to reach US$ 204 million by 2029, grow.....
SynopsisProleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Proleukin market size is expected to reach US$ 204 million by 2029, growing .....
SynopsisAcral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Acral Lentiginous Melanoma Drugs market size is expec.....
SynopsisAcral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Acral Lentiginous Melanoma Treatment market size is e.....
SynopsisAcral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Acral Lentiginous Melanoma market size is expected to.....
SynopsisOctreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. The global Sandostatin LAR mar.....
SynopsisPasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Pasireotide market size is expected to reach US$ 125 million by 2029, gr.....
SynopsisSignifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Signifor market size is expected to reach US$ 125 million by 2029, growing .....
SynopsisLanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Lanreotide market size is expected to reach US$ 1506.5 million by 2029, growing at a CAGR of 1......
